Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Katherine McGurk

Orthopaedic Surgery Summerville, SC Medical Doctor

NPI 1154816031 CMS profile 4825167

300 Callen Blvd Ste 330, Summerville, SC 29486

Open in the dashboard

General payments

$18,084

54 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine McGurk of Summerville, SC is reported in the CMS Open Payments database as having received $18,084 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $333 5
2024 General $2,246 14
2023 General $13,541 21
2022 General $259 3
2021 General $824 6
2020 General $541 3
2019 General $340 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine McGurk
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Katherine McGurk were reported at $333. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Katherine McGurk Orthopaedic Surgery median Middle half National median
2019 $340 $644 $140–$2,844 $163
2020 $541 $312 $75–$1,860 $114
2021 $824 $520 $117–$2,495 $132
2022 $259 $598 $128–$2,731 $149
2023 $13,541 $461 $128–$2,264 $160
2024 $2,246 $497 $134–$2,475 $164
2025 $333 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $10,455 3 payments
  2. AxoGen $2,539 15 payments
  3. Acumed LLC $1,537 8 payments
  4. Medical Device Business Services, Inc. $940 4 payments
  5. Skeletal Dynamics Inc $707 7 payments
  6. Piedmont Plus Innovation $531 1 payment
  7. Kerecis Limited $377 3 payments
  8. DePuy Synthes Sales Inc. $288 3 payments
  9. Endo Pharmaceuticals Inc. $226 2 payments
  10. Stryker Corporation $172 1 payment
  11. Other $312 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $10,000 1 payment
  2. Travel and Lodging $3,786 13 payments
  3. Food and Beverage $3,359 36 payments
  4. Education $940 4 payments
Products named General payments · program years 2019–2025
  1. Avance Nerve Graft $2,539 15 payments
  2. AxoGuard Nerve Connector $1,732 7 payments
  3. AXOGUARD NERVE PROTECTOR $1,732 7 payments
  4. INnate Implant $1,381 7 payments
  5. ACUMED $1,230 4 payments
  6. InFrame Implant $1,230 4 payments
  7. Geminus $707 7 payments
  8. Align $707 7 payments
  9. IJS $707 7 payments
  10. IMPlate $707 7 payments
  11. Other $4,873 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

69

Median for Orthopedic Surgery: 203

Drug cost

$210

Median for Orthopedic Surgery: $1,433

Branded share of claims

50.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $130
Oxycodone Hcl Generic 16 $55
Ondansetron Hcl Generic 18 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$31,486

Of which drugs: $5,582

Medicare patients

136

Average age 74

Services billed

534

75 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 59%
Diabetes 26%
Depression 21%
Ischemic heart disease 19%
Cancer 19%
Chronic kidney disease 18%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 51 80 $452

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record